RUBICON

Rubicon Research Limited
Small-capPharma ↗

What the six lenses say about RUBICON — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1748.4
2026-09-08
VWAP · 1Y anchor
₹950
+84.0% from VWAP
P/E · TTM
113.8×
TTM EPS ₹15.4
52-week range
93%
position low→high
RSI(14)
55
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How RUBICON’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD788›

The actual numbers

Price vs VWAP (1y)+84.0%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+66.2%
Price vs 50-EMA+10.0%
RSI(14)55
RS vs Nifty 500 · 3M+43.6%
RS vs sector · 3M+37.5%
52-week range93%
Volume vs 30d avg0.84×
Volume vs 60d avg0.82×
ATR(14) · volatility83.8
Bollinger width · vol contraction0.141
FundamentalD864›

The actual numbers

Return on equity (ROE)19.2%
Operating margin20.8%
Net margin14.1%
Debt / equity0.24×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)113.8×
TTM EPS₹15.4
52-week range93%
CatalystD539›

The actual numbers

Earnings & momentum32
Capital actions30
Governance80

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding59.9%
Delivery · 30d avg44.8%
Up/down-day asymmetry0.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D7 + D5 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
84
Conviction score 84/100 · avg-decile strength 6.0/10

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.6pp
-2.7pp
+17.5pp
+45.2pp
+131.0pp
—
Nifty 500
Broad-market baseline
-0.7pp
-2.7pp
+16.4pp
+43.6pp
+125.3pp
—
Sector
Own-sector index
—
—
+13.6pp
+37.5pp
+112.2pp
—

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

RUBICON daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1748.40-19.90

Relative strength

RS vs baseline · rebased to 100

RUBICON ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
283.22-2.02

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricSep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)296313358352412476514
↳ change QoQ—+5.7%+14.4%-1.7%+17.0%+15.5%+8.0%
EBITDA (₹cr)6270727994108119
EBITDA margin20.9%22.4%20.1%22.4%22.8%22.7%23.2%
PAT (₹cr)34383643547377
↳ change QoQ—+11.8%-5.3%+19.4%+25.6%+35.2%+5.5%
Net margin11.5%12.1%10.1%12.2%13.1%15.3%15.0%
EPS (₹)2.272.502.352.813.494.424.65
D/E———————
YoY growth · Mar '26Revenue +43.6% YoYPAT +113.9% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

…and 5 more.

Ownership

Who holds RUBICON

Mutual funds holding RUBICON (10)

FundWeightAUM ₹crGrade
Kotak Midcap Reg Gr0.81%69,283
Bajaj Finserv Flexi Cap Reg Gr1.83%8,173
Motilal Oswal Small Cap Reg Gr4.43%7,605
PGIM India Flexi Cap Reg Gr0.54%5,898
HDFC Pharma and Healthcare Reg Gr1.61%2,940
TrustMF Small Cap Reg Gr1.08%2,860
Bajaj Finserv Small Cap Reg Gr4.09%2,364
Bajaj Multi Asst Allc Reg Gr1.40%1,943
Bajaj Balanced Advtg Reg Gr1.62%1,263
PGIM India ELSS Tax Saver Reg Gr0.69%718

ETFs holding RUBICON (0)

No tracked ETF holds RUBICON ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma